Google bans ads for ‘bad actors’ selling ‘deceptive treatments’


Tech giant Google will ban advertisements for experimental medical treatments on its platforms, announcing in a blog post it has seen an increase in “bad actors attempting to take advantage of individuals by offering untested, deceptive treatments.”

Google will still allow companies doing genuine biomedical research to advertise for clinical trials, but its new policy prohibits advertising for unproven or experimental medical techniques. This includes most stem cell therapy, cellular (non-stem) therapy, and gene therapy.

The Washington Post reported that the changes come as stem cell clinics have grown into a sprawling direct-to-consumer industry. Some clinics have been claiming to be able to help patients with various ailments, including multiple sclerosis and degenerative lung diseases. A ground-breaking case in June saw a victorious lawsuit by the Food and Drug Administration against a Florida company, US Stem Cell, which has reportedly blinded at least four patients after injecting its “treatment” into their eyes. 

The Google policy changes have been welcomed by professional medical associations, including the International Society for Stem Cell Research and Stem Cells (ISSCR) in Australia. ISSCR president Deepak Srivastava remarked in a statement that:

“While stem cells have great potential to help us understand and treat a wide range of diseases, most stem cell interventions remain experimental and should only be offered to patients through well-regulated clinical trials.”

The full Google healthcare and medicines policy can be accessed online.

Nic Zumaran writes from Sydney.




MORE ON THESE TOPICS | google, stem cell treatments

This article is published by Nic Zumaran and BioEdge under a Creative Commons licence. You may republish it or translate it free of charge with attribution for non-commercial purposes following these guidelines. If you teach at a university we ask that your department make a donation. Commercial media must contact us for permission and fees. Some articles on this site are published under different terms.

 
 Search BioEdge

 Subscribe to BioEdge newsletter
rss Subscribe to BioEdge RSS feed

 
comments powered by Disqus